Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms
| Autor: | Pierre Olivier Vedrine, Danièle Sommelet, Laurent Coffinet, Karine Montagne, Claude Simon, Odile Oberlin, Michel Lapeyre, Stéphane Temam, Daniel Orbach |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Adolescent Lymphoma medicine.medical_treatment Brain tumor Gastroenterology Mucoepidermoid carcinoma Internal medicine Rhabdomyosarcoma medicine Carcinoma Humans Child Survival rate business.industry Precursor Cell Lymphoblastic Leukemia-Lymphoma Salivary Gland Neoplasms medicine.disease Neoplasms Neuroepithelial Radiation therapy Otorhinolaryngology Child Preschool Carcinoma Mucoepidermoid Female Sarcoma business |
| Zdroj: | Head & Neck. 28:827-833 |
| ISSN: | 1097-0347 1043-3074 |
| DOI: | 10.1002/hed.20429 |
| Popis: | Background. Salivary gland tumors represent 1% of head and neck tumors, with only 5% of these occurring in patients younger than 20 years. Mucoepidermoid carcinoma (MEC) is one of the most frequent salivary gland cancers among adults and children. Methods. This survey was conducted among 34 French pediatric oncology departments. From 1980 to 2000, 18 cases were reported. Results. Treatment included surgery or radiotherapy, or both. The 5-year survival rate was 93.7%. Eleven patients had been previously treated by radiotherapy and/or chemotherapy for a first malignant tumor, specifically, lymphoid leukemia (n = 4), lymphoma (n = 3), brain tumor (n = 2), sarcoma (n = 1), and retinoblastoma(n= 1). Conclusions. MEC is very rare in the pediatric age group. Treatment involves surgical removal of the tumor plus radiotherapy, according to histologic staging. MEC has a good prognosis in young patients. The survival rate does not differ in the subgroup of patients with MEC as a secondary tumor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text